Shots:
- The P-III (KEYNOTE-905/EV-303) trial randomized cisplatin-ineligible MIBC pts to Arm A (3 cycles of Keytruda + surgery with 14 subsequent cycles), Arm B (surgery alone), or Arm C (3 cycles of Keytruda + Padcev before surgery, followed 6 cycles of the combination, then 8 cycles of Keytruda alone)
- Arms C & B showed improved EFS (1EP) with benefits in OS & pCR (2EPs); trial will continue to assess 2EPs of EFS, OS & pCR in Arms A & B
- Keytruda is also being assessed in P-III (KEYNOTE-866, KEYNOTE-992, & KEYNOTE-B15) trials for MIBC, plus P-III (KEYNOTE-676) trial with BCG for NMIBC, & as a adj. therapy for localized muscle-invasive & locally advanced urothelial carcinoma in P-III (KEYNOTE-123) trial
Ref: Merck| Image: Merck and Pfizer | Press Release
Related News:- XtalPi and Pfizer Expand Partnership to Advance AI-Driven Drug Discovery and Materials Simulation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
